Blogs
Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease. XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO® First Randomized Study to
AbbVie will present a total of 23 abstracts across several tumor types including brain cancer, hematologic malignancies, breast cancer, lung cancer and other solid tumors. Researchers will present efficacy and safety data on depatuxizumab mafodotin, an antibody-drug conjugate (ADC) being studied for the treatment of adults with amplified EGFR newly diagnosed or recurrent GBM. The most common genetic alteration in GBM, EGFR-amplification, occurs in approximately 50 percent of GBM patients. Additional presentation include data from
Liquid Biopsy is a term given to a minimally invasive method of analyzing Tumor cell DNA circulating in the blood. This is a useful and very promising approach and opens new vistas compared to the Biochemical Biomarkers and Tissue Biopsies dependent monitoring of cancer. However, it throws its own challenges too. Circulating Tumor Cell DNA is present in the blood in a very miniscule amount. Cell free DNA (CfDNA) in itself is very small and
At ASCO 2017, the steadily increasing competitive intensity between Lonsurf (TAS-102, Taiho) and Stivarga (regorafenib, Bayer) will be on display . In addition, the I/O agents are reading out both as monotherapy in specific (dMMR/MSI-H) patient segments, as well as in combinations with other cytotoxic and targeted agents in broader patient segments, across treatment lines. Taiho and Elsevier will be communicating significantly on the real-world confirmation of Lonsurf´s RECOURSE trial. Bayer will continue to emphasize on
ASCO 2017 is primarily setting the stage for future as it relates to Prostate Cancer – a large number of presentations are focused on early stage data from new compounds and/or combinations of existing. The truly practice impacting trials such as IMbassador250, ARASENS, PROfound and TRITON3 will be touched upon as it relates to their design and current status. But we will have to wait for future ASCOs for their readouts. The major Prostate Cancer
Colorectal Cancer Diagnostics and monitoring CRC diagnostics and monitoring follows two pronged strategy Diagnostic tools such as Colonoscopy: Specific, Can Remove Polyps and Take Biopsies. Adverse: Can cause perforation, Can miss small adenomas Flexible sigmoidoscopy: Specific, Can Remove Polyps and Take Biopsies. Adverse: Reduced risk of perforation Double-contrast barium enema: Specific Can miss some Adenomas Computer tomographic colonography Lab Diagnosis using Biomarkers such as Fecal Occult Blood Test: Cheap for screening, Non Specific Stool DNA